Chemistry:Pralurbactam
From HandWiki
Pralurbactam is an investigational new drug that is being evaluated by Qilu Pharmaceutical for the treatment of hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP). It is a DBO class β-lactamase inhibitor that is co-administered with β-lactam antibiotics to overcome bacterial resistance to the later.[1][2][3]
Clinical trials
Pralurbactam is in phase 3 clinical trials for HAP and VAP.[4]
References
- ↑ "Pralurbactam - Qilu Pharmaceutical". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800080104.
- ↑ "FL058, a novel β-lactamase inhibitor, increases the anti-Mycobacterium abscessus activity of imipenem". International Journal of Antimicrobial Agents 65 (2). February 2025. doi:10.1016/j.ijantimicag.2024.107414. PMID 39710142.
- ↑ "An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens". Expert Opinion on Drug Metabolism & Toxicology: 1–40. June 2026. doi:10.1080/17425255.2026.2691051. PMID 42317028.
- ↑ Clinical trial number NCT07327619 for "A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP" at ClinicalTrials.gov
 |  |
